SG10201903119QA - Polypeptide vaccine - Google Patents
Polypeptide vaccineInfo
- Publication number
- SG10201903119QA SG10201903119QA SG10201903119QA SG10201903119QA SG10201903119QA SG 10201903119Q A SG10201903119Q A SG 10201903119QA SG 10201903119Q A SG10201903119Q A SG 10201903119QA SG 10201903119Q A SG10201903119Q A SG 10201903119QA SG 10201903119Q A SG10201903119Q A SG 10201903119QA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide vaccine
- cancer
- prevention
- vaccine
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Polypeptide Vaccine We provide a polypeptide vaccine for treatment and prevention of cancer, particularly prevention of metastasis of cancer. Also provided are methods of treating or preventing cancer, and pharmaceutical compositions comprising the polypeptide vaccine. [Figure17]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161531290P | 2011-09-06 | 2011-09-06 | |
SG2012011581A SG193038A1 (en) | 2012-02-17 | 2012-02-17 | Polypeptide vaccine |
SG2012046447 | 2012-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201903119QA true SG10201903119QA (en) | 2019-05-30 |
Family
ID=54259018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201903119QA SG10201903119QA (en) | 2011-09-06 | 2012-08-29 | Polypeptide vaccine |
SG11201400432VA SG11201400432VA (en) | 2011-09-06 | 2012-08-29 | Polypeptide vaccine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201400432VA SG11201400432VA (en) | 2011-09-06 | 2012-08-29 | Polypeptide vaccine |
Country Status (6)
Country | Link |
---|---|
US (2) | US10258676B2 (en) |
EP (1) | EP2753345B1 (en) |
JP (2) | JP6153526B2 (en) |
CN (2) | CN103987396A (en) |
SG (2) | SG10201903119QA (en) |
WO (1) | WO2013036201A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2533806B1 (en) | 2010-02-10 | 2019-09-04 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
US20140005119A1 (en) * | 2012-06-28 | 2014-01-02 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS |
US20170049870A1 (en) * | 2012-08-10 | 2017-02-23 | Kanagawa Prefectural Hospital Organization | Antigen Peptide Derived From the Sequence of Epidermal Growth Factor Receptor Having T790M Point Mutation |
WO2014024965A1 (en) * | 2012-08-10 | 2014-02-13 | 学校法人 久留米大学 | Antigen peptide originated from t790m point-mutated sequence of epidermal growth factor receptor |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
EP3119426A4 (en) * | 2014-03-19 | 2018-02-28 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
WO2015143223A1 (en) | 2014-03-19 | 2015-09-24 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CA2954279C (en) * | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
SG10201404895XA (en) * | 2014-08-13 | 2016-03-30 | Agency Science Tech & Res | Diagnosis |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
KR20180010229A (en) | 2015-05-20 | 2018-01-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | Shared neointimal antigen |
WO2017120576A1 (en) * | 2016-01-07 | 2017-07-13 | Duke University | Cancer vaccines and methods of delivery |
US20190381158A1 (en) * | 2016-02-04 | 2019-12-19 | Duke University | Cell-based vaccine compositions and methods of use |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
BR112019015797A2 (en) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS THAT CODE ACTIVATING ONCOGEN MUTATION PEPTIDES |
CN113677351A (en) * | 2018-12-20 | 2021-11-19 | 芝加哥大学 | Methods and compositions related to therapeutic peptides for cancer therapy |
EP4056197A4 (en) * | 2019-11-07 | 2023-09-06 | Shenzhen Gino Biotechnology Co., Ltd. | Tumor-specific polypeptide sequence and use thereof |
CN111072763A (en) * | 2019-12-23 | 2020-04-28 | 维塔恩(广州)医药有限公司 | Tumor-associated gene GNAS mutation-associated antigen short peptide and application thereof |
CN111393509B (en) * | 2020-03-30 | 2022-03-29 | 国家纳米科学中心 | Target specific polypeptide and application thereof |
CN111285935B (en) * | 2020-05-13 | 2020-09-11 | 方达医药技术(上海)有限公司 | Antibody for specifically detecting BRAF gene mutation and application thereof in preparation of cancer detection kit |
EP4337677A1 (en) * | 2021-05-14 | 2024-03-20 | Oslo University Hospital | Mutated gnas peptides |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69031120T2 (en) | 1989-05-19 | 1998-01-15 | Genentech Inc | HER2 EXTRACELLULAR DOMAIN |
IL102964A0 (en) * | 1991-08-26 | 1993-01-31 | Cytel Corp | Hla-restricted hepatitis b virus ctl epitopes |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
EP0793501A4 (en) * | 1994-12-14 | 2000-05-03 | Scripps Research Inst | In vivo activation of tumor-specific cytotoxic t cells |
US6514942B1 (en) * | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
US7329410B1 (en) * | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
AU2001243196A1 (en) | 2000-02-22 | 2001-09-03 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
US7105642B2 (en) | 2001-08-03 | 2006-09-12 | Cell Signalling Technology, Inc. | Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof |
JP4579836B2 (en) | 2004-01-23 | 2010-11-10 | 株式会社グリーンペプタイド | Epidermal growth factor receptor (EGFR) -derived peptide |
US7976852B2 (en) * | 2005-04-26 | 2011-07-12 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
CN101171032B (en) * | 2005-05-09 | 2012-02-29 | 瓦克松生物技术公司 | Use of native peptides and their optimized derivatives for vaccination |
WO2007110098A1 (en) * | 2006-03-29 | 2007-10-04 | Institut National De La Sante Et De La Recherche Medicale | HBx PEPTIDES, CAPABLE OF ELICITING A PROMISCUOUS IMMUNODOMINANT CD4+ RESPONSE DIRECTED AGAINST HBV |
WO2008008311A1 (en) | 2006-07-10 | 2008-01-17 | The Trustees Of The University Of Pennsylvania | Methods for administering tumor vaccines |
EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
JP2010530735A (en) * | 2007-05-03 | 2010-09-16 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Antibody binding to intracellular PRL-1 polypeptide or PRL-3 polypeptide |
JP2010535503A (en) * | 2007-08-10 | 2010-11-25 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ(エー*エスティーエーアール) | VHZ for cancer diagnosis and treatment |
KR100995340B1 (en) * | 2007-11-19 | 2010-11-19 | 재단법인서울대학교산학협력재단 | Vaccine comprising Monocyte or immature myeloid cellsIMC which was loaded with the ligand of natural killer T cell and antigen |
JP5756014B2 (en) * | 2008-08-08 | 2015-07-29 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) | VHZ for cancer diagnosis and treatment |
KR101689408B1 (en) * | 2008-10-17 | 2016-12-23 | 다나-파버 캔서 인스티튜트 인크. | MUC-1 cytoplasmic domain peptides as inhibitors of cancer |
EP2506864B1 (en) | 2009-11-30 | 2016-07-27 | Agency For Science, Technology And Research | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
EP2627671A1 (en) * | 2010-10-15 | 2013-08-21 | Université Libre de Bruxelles | Estrogen receptor alpha polypeptide sequence, diagnostic and therapeutic applications thereof |
CN102675424B (en) | 2011-03-15 | 2014-02-05 | 天津托普泰克生物科技有限公司 | Polypeptide drug for resisting Hepatitis B virus X protein |
CN102675423B (en) | 2011-03-15 | 2014-02-05 | 天津托普泰克生物科技有限公司 | Polypeptide medicine against hepatitis B virus X protein |
CN102675422B (en) | 2011-03-15 | 2014-02-05 | 天津托普泰克生物科技有限公司 | Polypeptide drug against hepatitis B virus X protein (HBx) |
EP2562205A1 (en) * | 2011-08-22 | 2013-02-27 | Rhein Chemie Rheinau GmbH | New films for solar cells |
CN102357246B (en) | 2011-11-02 | 2013-04-03 | 江苏省中医药研究院 | EGFR and HER2 combined polypeptide epitope vaccine |
-
2012
- 2012-08-29 SG SG10201903119QA patent/SG10201903119QA/en unknown
- 2012-08-29 SG SG11201400432VA patent/SG11201400432VA/en unknown
- 2012-08-29 EP EP12830226.2A patent/EP2753345B1/en active Active
- 2012-08-29 JP JP2014529643A patent/JP6153526B2/en active Active
- 2012-08-29 WO PCT/SG2012/000305 patent/WO2013036201A1/en active Application Filing
- 2012-08-29 US US14/342,644 patent/US10258676B2/en active Active
- 2012-08-29 CN CN201280054509.3A patent/CN103987396A/en active Pending
- 2012-08-29 CN CN201810214453.2A patent/CN108434440B/en active Active
-
2017
- 2017-05-30 JP JP2017106379A patent/JP6676584B2/en active Active
-
2019
- 2019-03-19 US US16/358,400 patent/US20200101147A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2017186352A (en) | 2017-10-12 |
US20150306196A1 (en) | 2015-10-29 |
CN108434440A (en) | 2018-08-24 |
US10258676B2 (en) | 2019-04-16 |
JP6676584B2 (en) | 2020-04-08 |
US20200101147A1 (en) | 2020-04-02 |
CN108434440B (en) | 2022-08-23 |
EP2753345A1 (en) | 2014-07-16 |
JP2014526462A (en) | 2014-10-06 |
SG11201400432VA (en) | 2014-08-28 |
JP6153526B2 (en) | 2017-06-28 |
WO2013036201A1 (en) | 2013-03-14 |
EP2753345B1 (en) | 2016-07-13 |
EP2753345A4 (en) | 2015-03-25 |
CN103987396A (en) | 2014-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201903119QA (en) | Polypeptide vaccine | |
IL276434A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
IL279330A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
MX2020011772A (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer. | |
MD4589B1 (en) | Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus | |
WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
MX356525B (en) | Aav -vectors for use in gene therapy of choroideremia. | |
RS56187B1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
MX350868B (en) | MEDICAMENTS and METHODS FOR TREATING CANCER. | |
GB201114923D0 (en) | Immunogenic proteins and compositions | |
EP2575766A4 (en) | Novel pharmaceutical compounds | |
TN2010000463A1 (en) | Compositions and methods for preparing and using same |